APA (7th ed.) Citation

Qu, W., Ding, Z., Qu, X., Tang, Z., Zhu, G., Fu, X., . . . Shi, Y. (2022). Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: Real-world study. BJS open, 6(5), . https://doi.org/10.1093/bjsopen/zrac114

Chicago Style (17th ed.) Citation

Qu, Wei-Feng, et al. "Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma Using a Combination of Toripalimab, Lenvatinib Plus TACE: Real-world Study." BJS Open 6, no. 5 (2022). https://doi.org/10.1093/bjsopen/zrac114.

MLA (9th ed.) Citation

Qu, Wei-Feng, et al. "Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma Using a Combination of Toripalimab, Lenvatinib Plus TACE: Real-world Study." BJS Open, vol. 6, no. 5, 2022, https://doi.org/10.1093/bjsopen/zrac114.